12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Kalydeco ivacaftor regulatory update

Australia's Therapeutic Goods Administration ( TGA) approved Kalydeco ivacaftor from Vertex to treat cystic fibrosis in patients >=6 years who have at least 1...

Read the full 102 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >